Standard immunohistochemistry efficiently screens for anaplastic lymphoma kinase rearrangements in differentiated thyroid cancer

Gahee Park^{1,5,*}, Tae Hyuk Kim^{2,*}, Hae-Ock Lee¹, Jung Ah Lim^{2,6}, Jae-Kyung Won³, Hye Sook Min³, Kyu Eun Lee⁴, Do Joon Park², Young Joo Park² and Woong-Yang Park^{1,5,7}

¹Samsung Genome Institute, Samsung Medical Center, 50 Irwondong, Gangnamgu, Seoul 135-710, Korea
Departments of ²Internal Medicine, ³Pathology ⁴Surgery, and ⁵Biomedical Sciences, Seoul National University College of Medicine, Seoul, Korea

⁶Department of Internal Medicine, Eulji University School of Medicine, Eulji General Hospital, Seoul, Korea

⁷Department of Molecular Cell Biology, Sungkyunkwan University School of Medicine, Suwon, Korea

*G Park and T H Kim contributed equally to this work)

Correspondence should be addressed to W-Y Park

Email
woongyang.park@samsung.com

Abstract

The anaplastic lymphoma kinase (*ALK*) gene is frequently rearranged in various types of cancer and is highly responsive to targeted therapeutics. We developed a system to detect rearrangement of *ALK* in a large group of Korean thyroid cancer patients. We screened 474 malignant or benign thyroid tumor cases to identify *ALK* fusions. Expression and translocation of the *ALK* gene were analyzed by immunohistochemistry (IHC), fluorescence *in situ* hybridization (FISH), and digital multiplexed gene expression (DMGE) analysis in formalin-fixed paraffin-embedded tissues. Four cases of rearrangement of *ALK* were detected by IHC, and these cases were validated with FISH on 189 samples. On the other hand, DMGE analysis using Nanostring detected three out of four IHC-positive cases. Two rearrangements of *ALK* were striatin (*STRN*)–*ALK* fusions, which were identified by 5' RACE analysis. Rearrangements of *ALK* were found exclusively in v-raf murine sarcoma viral oncogene homolog B (*BRAF*) WT papillary carcinomas. Given the wide availability and accuracy of IHC for detecting ectopic expression of *ALK* in the thyroid, we suggest that IHC-based screening can be a practical method for identifying patients with *ALK* rearrangements in differentiated thyroid cancer.

Key Words

- ▶ thyroid cancer
- ▶ ALK
- ▶ gene rearrangement
- ▶ immunohistochemistry

Endocrine-Related Cancer
(2015) 22, 55–63

Introduction

Differentiated thyroid cancer (DTC) is a common endocrine malignancy, and its prevalence is increasing worldwide (Chen *et al.* 2009). The majority of patients with DTC have favorable outcomes after standard therapy that combines surgery, radioactive iodine ablation, and thyroid-stimulating hormone suppression. Nonetheless, in approximately 30% of these treated DTC patients, tumors persist or recur (Mazzaferri & Kloos 2001).

In a recent analysis, the DTC cohorts with structurally incomplete response to the initial therapy were found to have a 10-year survival that approached only 50% (Vaisman *et al.* 2011). As these patients were more likely to have ¹⁸F-fluorodeoxyglucose positron-emission-tomography-positive and non-radioactive-iodine-avid disease, the current National Comprehensive Cancer Network guidelines recommend the use of small-molecule

kinase inhibitors for treatment, given the limited efficacy of cytotoxic chemotherapy (http://www.nccn.org/professionals/physician_gls/pdf/thyroid.pdf; accessed 26th April 2014).

Identification of the mutations driving DTC prompted the therapeutic use of oral multikinase inhibitors such as sorafenib, which targets rearranged during transfection (RET), v-raf murine sarcoma viral oncogene homolog B (BRAF), and vascular endothelial growth factor receptor (Brose *et al.* 2014). More recently, rearrangements of anaplastic lymphoma kinase (ALK) that lead to both ectopic expression and constitutive activation of the ALK fusion protein were reported in DTC and anaplastic carcinoma (Godbert *et al.* 2014, Kelly *et al.* 2014). Treatment with clinically available ALK inhibitors, such as crizotinib and TAE684, yielded *in vitro* antitumor efficacy (Kelly *et al.* 2014) and produced clinical improvement in anecdotal cases (Demeure *et al.* 2014, Godbert *et al.* 2014).

To introduce these ALK inhibitors for the clinical treatment of thyroid cancer, the precise frequency of the ALK rearrangement in a wide range of thyroid tumors should be evaluated first. More importantly, a practical diagnostic assay for identifying rearrangements of ALK in thyroid cancer is essential. As is the case with non-small cell lung cancer (NSCLC), immunohistochemistry (IHC) may be a useful tool for screening for rearrangements of ALK in thyroid cancer, as the expression of ALK is extremely limited during adulthood and occurs only in cancer tissues following chromosomal rearrangement (Mino-Kenudson *et al.* 2010, Shaw *et al.* 2013).

In this study, we performed comprehensive screening for rearrangements of ALK in a large group of paraffinized thyroid tumor samples using IHC with an ALK-specific

antibody. We then confirmed that the expression of ALK protein observed was concordant with rearrangement of ALK using fluorescence *in situ* hybridization (FISH) and digital multiplexed gene expression (DMGE) analysis. In addition, we reported the discovery of a striatin (STRN)–ALK gene rearrangement in a solid variant, the aggressive histological subtype, and the clinicopathological characterization of ALK-rearranged papillary carcinoma.

Subjects and methods

Case selection

This study included 474 formalin-fixed paraffin-embedded (FFPE) samples from patients with benign and malignant thyroid tumors collected from 1993 to 2002 ($n=256$) and from 2010 to 2012 ($n=218$; Table 1). The samples were collected using a protocol approved by the Institutional Review Board Committee of Seoul National University Hospital.

Two cores of 2.0-mm tissue were obtained from the most representative area of the individual cases, and a tissue microarray block was constructed as described previously (Garcia-Gonzalez *et al.* 2005). The BRAF^{V600E} mutation was prescreened in samples of papillary carcinomas using the PCR, restriction fragment length polymorphism analysis, and direct sequencing. We also included 29 matched fresh-frozen samples of WT BRAF papillary carcinoma for detailed genomic analysis. Medical records of the cases with ALK rearrangements were reviewed to extract data including demographic characteristics, histological subtype, tumor–nodes–metastases (TNM) staging according to the Seventh American Joint Committee on Cancer (Edge *et al.* 2010), and clinical course.

Table 1 Summary of study samples screened for rearrangement of ALK

Histology	Sample type	ALK IHC		ALK FISH		ALK Nanostring	
		Positive (n)	Total (n)	Positive (n)	Total (n)	Positive (n)	Total (n)
Papillary carcinoma							
WT BRAF	Fresh-frozen and FFPE	1	29	1	29	1	29
	FFPE	3	233	3	189	2 ^a	3
BRAF ^{V600E} mutant	FFPE	0	79	ND	ND	ND	ND
Follicular carcinoma	FFPE	0	25	ND	ND	ND	ND
Hurthle cell carcinoma	FFPE	0	9	ND	ND	ND	ND
Anaplastic carcinoma	FFPE	0	17	ND	ND	ND	ND
Benign thyroid tumor							
Follicular adenoma	FFPE	0	57	ND	ND	ND	ND
Hurthle cell adenoma	FFPE	0	25	ND	ND	ND	ND
Total		4	474	4	218	3	32

FFPE, formalin-fixed paraffin-embedded; ND, not done.

^aThe Nanostring result for patient 4 seemed to be a false negative because the remaining amount of FFPE sample was insufficient after FISH and IHC analyses.

Immunohistochemistry

IHC staining was performed in FFPE tissue microarray sections that were 4 µm thick using an automated immunostainer (Leica Microsystems, Milton Keynes, UK). Briefly, the slides were heated for 20 min at 100 °C in Epitope retrieval solution, pH 9.0 (Leica Microsystems). The slides were then incubated with a monoclonal mouse anti-human ALK antibody (Novocastra, Newcastle Upon Tyne, UK) at a dilution of 1:25. This antibody was raised against a C-terminal portion of the tyrosine kinase domain of ALK and was intended for the qualitative identification of ALK molecules in paraffin sections by light microscopy. Staining intensity was scored as 0 (no staining), 1+ (weak cytoplasmic staining without any background staining), and 2+ (strong cytoplasmic staining). Tumors with 1+ or 2+ expression in more than 10% of the tumor cells were deemed positive for ALK protein expression (Yi et al. 2011, Park et al. 2012). For ALK IHC-positive cases, we subsequently performed IHC using an antibody against phosphorylated ALK (phosphor Y1507, Abcam, Cambridge, MA, USA) at a dilution of 1:100.

Fluorescence in situ hybridization

ALK rearrangements in FFPE tumor tissues were detected by FISH analysis using a break apart probe specific for the ALK locus (Vysis, Abbott Molecular), according to the manufacturer's instructions. Cases were defined as positive by FISH when tumors harbored split signals in more than 15% of cells or an isolated red (3') signal in tumor cells as described previously (Kim et al. 2013, Kelly et al. 2014).

RNA isolation from FFPE and fresh-frozen samples

Six sections from archived FFPE blocks were used for RNA extraction using a High Pure FFPE RNA Isolation kit (Roche). AllPrep DNA/RNA Minikit (Qiagen) was used for RNA isolation from the fresh-frozen biopsy samples. The extracted RNA was quantified and its quality was assessed using a Nanodrop 8000 (Thermo Scientific, Waltham, MA, USA) and a Bioanalyzer 2100 (Agilent, Santa Clara, CA, USA).

5' RACE

To determine the N-terminal ALK partner, a SMARTer RACE cDNA Amplification Kit (Clontech) was used according to the manufacturer's instructions (Supplementary Fig. 1, see section on supplementary data given at the end of this article). Touchdown PCR was performed using LA HS Taq DNA polymerase (Clontech)

with the following primers: ALK-gene-specific primer 1 (5'-CCGCCATGAGCTCCAGCAGGATGAAC-3'), Universal Primer A Mix, ALK-gene-specific primer 2 (5'-CAGGGC-TTCCATGAGGAAATCCAGT-3'), and Nested Universal Primer A. Amplified products were ligated into the pGEM-T easy Vector (Promega) and subjected to nucleotide sequencing (Macrogen, Seoul, Korea).

RT-PCR for STRN-ALK

To verify the presence of STRN-ALK fusion transcripts, cDNA was synthesized from total RNA of fresh-frozen and FFPE samples using the ReverTra Ace qPCR RT Kit (Toyobo, Osaka, Japan). The PCR was performed with 35 cycles of denaturation at 94 °C for 30 s, annealing at 60 °C for 1 min, and elongation at 72 °C for 1 min. The specific fusion primers for STRN-ALK were as follows: STRN exon 3 forward primer (5'-CGGGACAGAATTGAATCAGG-3') and ALK exon 20 reverse primer (5'-TGCCAGCAAAGCAGTAGTTG-3').

Nanostring nCounter analysis

According to the manufacturer's instructions (Nanostring Technologies, Inc., Seattle, WA, USA), the nCounter assay was performed in order to confirm potential 'fusion calls' in a total of 32 FFPE samples of papillary carcinoma. In brief, 200 ng of total RNA from FFPE and selected fresh-frozen samples were hybridized to nCounter reporter probe sets (Supplementary Table 1 and Supplementary Fig. 2, see section on supplementary data given at the end of this article) for 16 h at 65 °C. The hybridized samples were transferred to the nCounter Sample Prep station, and the reporter signals were visualized using a digital analyzer and normalized using the nSolver analysis software version 1. The background threshold was calculated from negative controls for a potential 'fusion call'. The calculation was performed as follows: $ALK3'/5' = E_3 / \text{Max}(A_5, B)$, where E_3 is the geometric mean of ALK 3' probe expression, A_5 is the average of ALK 5' probe expression, and B is the background threshold as defined previously (Lira et al. 2013, Fang et al. 2014). The thresholds for RET and fusion probes were calculated in a similar manner as described previously (Lira et al. 2013, Fang et al. 2014).

Results

Identification of STRN-ALK fusion in fresh tissue samples

To search for ALK rearrangements in thyroid cancer, we first examined FFPE samples from 29 cases of papillary

carcinoma with WT *BRAF* that also had fresh frozen tissue available. Of these, one case (patient 1) showed strong cytoplasmic staining for ALK by IHC (Fig. 1A), indicative of abnormal expression due to rearrangement of *ALK*. The break apart FISH assay confirmed rearrangement of *ALK* through visual splitting of one pair of red and green signals (Fig. 1B). The remaining 28 samples exhibited fused signals (Fig. 2H), indicating normal *ALK* status.

We then performed 5' RACE to identify the *ALK* fusion partner in both fresh-frozen and FFPE samples from patient 1. As shown in Fig. 1C, exon 3 of *STRN*, was fused with exon 20 of *ALK*, generating a *STRN*–*ALK* fusion. The fusion was further verified by RT-PCR with specific primers for 5'–*STRN* and 3'–*ALK* (Fig. 1D). This fusion event has been reported recently in a study that examined gene rearrangements in thyroid cancer by paired-end RNA sequencing (Kelly et al. 2014).

Patient screening using ALK IHC in archival paraffinized samples

To determine the frequency of rearrangements of *ALK* in thyroid tumors, we screened a tissue microarray of FFPE samples archived from 1993 to 2002. The samples consisted of 123 papillary carcinomas (44 *BRAF* WT, 79 *BRAF*^{V600E} mutants), 25 follicular carcinomas, nine Hurthle cell carcinomas, 17 anaplastic carcinomas, and 82 benign thyroid tumors (Table 1). A positive result for ALK screening by IHC was not obtained for any of these cases. To enrich for ALK-positive cases, the array of *BRAF* WT papillary carcinomas archived consecutively from 2010 to 2012 was further screened. Among the 189 FFPE samples, three cases showed cytoplasmic ALK localization in IHC (Fig. 2). *ALK* FISH was performed on those 189 FFPE array samples including the three samples that were

positive for ALK by IHC. The results showed break apart or isolated red (3') signals for only these three, corroborating the results for IHC (Fig. 2). The 5' RACE analysis of the FFPE samples revealed one additional case (patient 2) with an *STRN*–*ALK* rearrangement but failed to determine specific fusion partners for the remaining two cases.

Subsequent IHC using an antiphosphorylated ALK antibody revealed activated expression of ALK protein in the four cases with rearranged *ALK* (Supplementary Fig. 3, see section on supplementary data given at the end of this article). As thyroid cancer commonly harbors *RET*/*PTC* translocations (Schlumberger 1998, Nikiforov & Nikiforova 2011), we also performed *RET* FISH on the *ALK*-rearranged cases; however, no rearrangements of *RET* were detected (data not shown), indicating exclusiveness. The overall frequency of rearrangements of *ALK* was 1.5% in the *BRAF* WT papillary carcinoma samples (four of 262). Other types of thyroid cancer, including *BRAF*^{V600E} mutant papillary carcinoma and benign thyroid tumors, did not harbor the *ALK* rearrangement.

Comparison between Nanostring and FISH for the detection of rearrangement of ALK

To explore an alternative screening method for the detection of *ALK* rearrangement, we employed the Nanostring nCounter assay (Suehara et al. 2012). This assay allows simultaneous detection of multiple translocations using limited amounts of archival paraffinized samples. For parallel comparison with other methods, a total of 32 FFPE samples of *BRAF* WT papillary carcinoma cases, including the four *ALK*-rearranged cases identified by IHC/FISH, were subjected to the Nanostring assay (Table 1). Using multiplexed probes to target either the 5' or the 3' exons of *ALK*, we assessed the 3'/5' exon

Figure 1

STRN–*ALK* fusion in patient 1 with solid variant papillary carcinoma. (A) Photomicrograph image of IHC using the anti-ALK antibody showing strong cytoplasmic staining (magnification: 200×). Confirmation of the *STRN*–*ALK* fusion by (B) FISH using the break apart *ALK* probe to show splitting of one pair of red and green signals (arrows) and by (C) nucleotide sequencing, which is accompanied by a schematic presentation of the *STRN*–*ALK* rearrangement. The fusion occurred between the ALK

C-terminal intracellular portion, which contains the tyrosine kinase (TK) domain, and the N-terminal portion of *STRN*, which contains the caveolin-binding domain (CB) and the coiled coil domain (CC). (D) Results for fusion-specific RT-PCR for *STRN*–*ALK* (53; A20, 179 bp). M and NTC indicate the size marker (100 bp ladder) and the non-template control respectively. P1–3 indicates patients 1–3. A full colour version of this figure is available via <http://dx.doi.org/10.1530/ERC-14-0467>.

Figure 2

Photomicrograph image of ALK IHC and FISH for patient 2 (A and B), patient 3 (C and D), patient 4 (E and F), and a representative patient with native *ALK* and *BRAF* genes as a control (G and H). IHC showed strong cytoplasmic staining in the tumor cells of patient 2 (A) and weak staining in

patients 3 (C) and 4 (E; magnification: 100×). White arrows indicate the split red and green signals that are indicative of *ALK* rearrangement. A full colour version of this figure is available via <http://dx.doi.org/10.1530/ERC-14-0467>.

imbalance. With a 3'/5' ratio of greater than two as a cut-off, three samples were deemed positive for *ALK* rearrangements. One discordant result (positive by IHC/FISH and negative by Nanostring) was obtained for patient 4, and this sample included an insufficient amount of RNA due to a limited quantity of sample, indicating that the discordance arose from sampling rather than the platform. For the remaining 28 patients, we confirmed the expression of native *ALK* (Table 2, Fig. 3 and Supplementary Table 2, see section on supplementary data given at the end of this article). We also assessed the presence of rearrangements of *RET* by Nanostring using probes that target the *RET* exonic imbalance or specific *RET/PTC* fusion junction. Out of 32 FFPE samples of *BRAF* WT papillary carcinoma, only one case exhibited the *RET/PTC* rearrangement (3.1%, Supplementary Fig. 4). Although the number of samples was limited, these results indicate that *ALK* and *RET* translocations are mutually exclusive as in the case of rearrangement of *ALK* and *BRAF*^{V600E} mutation (Kelly *et al.* 2014, Perot *et al.* 2014).

Clinical characteristics of patients with papillary carcinomas that harbor rearrangements of *ALK*

In this series of patients with papillary carcinomas with rearrangements of *ALK*, a distinct preference in terms of demographic factors or histological subtypes was not found (Table 2). All patients denied having a history of neck irradiation. Notably, the *STRN-ALK* rearrangement

was found in a young patient with solid variant papillary carcinoma. Patients with this variant are known to have a worse prognosis (Nikiforov *et al.* 2001). Patient 2, on the other hand, had small follicular variant papillary carcinoma, which is known to have a better prognosis. All four patients with rearrangement of *ALK* showed favorable responses to the initial surgery with or without radioactive iodine ablation therapy.

Discussion

Analysis of thyroid tumor tissue archives revealed that approximately 1.5% of *BRAF* WT papillary carcinomas harbor rearrangements of *ALK*. Our report is the largest study to date to report the frequency of rearrangements of *ALK* in thyroid cancer. An estimated 40 568 and 62 980 new cases of thyroid cancer each year are diagnosed in Korea (Korea Central Cancer Registry 2011) and the USA (Siegel *et al.* 2014) respectively. As a result, we extrapolated the number of patients with papillary carcinoma with rearrangements of *ALK* to be 192 in Korea and to be 468 in the USA, assuming that 90% of all thyroid cancers are papillary carcinoma and that the *BRAF*^{V600E} mutation rate of each country is 65 and 45% respectively (Kim *et al.* 2012). *ALK* is involved in the initiation and progression of many different cancer types (Mano 2012, Hallberg & Palmer 2013), including lymphoma, neuroblastoma, and NSCLC. Preclinical studies in thyroid cancer patients (Kelly *et al.* 2014), indicated that rearrangements of *ALK*

Table 2 Clinical and histological details of the four patients with papillary carcinoma with rearrangements of *ALK*

	Patient 1	Patient 2	Patient 3	Patient 4
Age (years)	13	50	36	48
Sex	Female	Female	Male	Female
History of neck irradiation	–	–	–	–
Preoperative cytology	Suspicious for papillary carcinoma	Atypia of undetermined significance	Suspicious for papillary carcinoma	Suspicious for papillary carcinoma
Surgery	TT with CND	TT with CND	TT with ipsilateral MRND	TT with ipsilateral MRND
Tumor size (cm)	2.8	0.6	1.9	0.7
Histological subtype	Solid	Follicular	Classic	Classic
Extrathyroidal extension	Microscopic	Microscopic	Microscopic	–
Multifocality	–	–	–	+ (bilateral)
Lymph node metastasis	0/7	0/8	2/13	2/15
Other pathology	Lymphocytic thyroiditis	Lymphocytic thyroiditis	Lymphocytic thyroiditis	Lymphocytic thyroiditis, nodular goiter
TNM staging	I (pT3N0)	III (pT3N0)	I (pT3N1b)	III (pT1aN1a)
<i>BRAF</i> ^{V600E}	WT	WT	WT	WT
Adjuvant radioactive iodine ablation (cumulative dose)	ND	Ablated (30 mCi)	Ablated (130 mCi)	Ablated (60 mCi)
Follow-up status (duration)	NED (17 months)	NED (24 months)	NED (30 months)	NED (34 months)
Tests for <i>ALK</i> rearrangement				
IHC	++	++	+	+
FISH	+	+	+	+
Nanostring (3':5' ratio)	+ (2.57)	+ (4.91)	+ (3.88)	– (0.92) ^a
Fusion partner	<i>STRN</i>	<i>STRN</i>	Unknown	ND

CND, central neck dissection; MRND, modified radical neck dissection; ND, not done; NED, no evidence of disease; TT, total thyroidectomy.

^aThe Nanostring result for patient 4 seemed to be a false negative, because the remaining amount of FFPE sample was insufficient after FISH and IHC analyses.

in thyroid cancers may also be sensitive to *ALK* inhibitors. Therefore, we expect that tumors with rearrangement of *ALK* will become a unique, targetable subset of thyroid cancer and that identification of this emerging biomarker will have an effect on the diagnosis and treatment of patients with advanced DTC.

Diagnostic tests for identifying rearrangements of *ALK* are important in clinical settings, as such tests can identify those patients who will probably benefit from a targeted therapy. Traditionally, FISH analysis using probes flanking the *ALK* locus has been used for the identification of this rearrangement (Villamor *et al.* 2008); however, FISH may not be the optimal technique for routine practice due to the high cost and need for technical expertise. The break apart signal patterns resulting from the intrachromosomal deletion (*STRN*–*ALK*) and inversion (*EML4*–*ALK*) are often subtle and can easily be missed by this method (Mino-Kenudson *et al.* 2010). Alternatively, Japanese researchers extracted RNA from stored FFPE samples and used highly sensitive RT-PCR in conjunction with 5' RACE to detect the presence of a high frequency of *EML4*–*ALK* rearrangements in papillary carcinomas from atomic bomb survivors (Hamatani *et al.* 2012).

In this study, papillary carcinomas with *ALK* rearrangement invariably expressed an *ALK* protein that could readily be identified in the paraffinized samples using IHC with an *ALK* MAB. Indeed, no false FISH-negative cases were present in the four IHC-positive cases. As the rearrangement of *ALK* results in loss of the transmembrane domain of *ALK* (Shaw *et al.* 2013), *ALK* IHC showed cytoplasmic staining in all of the rearranged cases. Given the wider availability and accuracy for detection of ectopic expression of *ALK* in the thyroid, we suggest that IHC-based screening should be used as a method for identifying thyroid cancer patients with rearrangements of *ALK*. As rearrangements of *ALK* represent a potential therapeutic target and FISH is a validated method for the detection of actual fusions that correlate with the response to treatment, we recommend the use of IHC as a screening procedure and the use of FISH for the final confirmation of rearrangement of *ALK*. If a FISH assay is not available, the critical issue in clinical settings would be to quickly determine whether expressed *ALK* protein is activated or not, as some papillary carcinomas express WT *ALK*. In that case, additional use of antibodies against phosphorylated *ALK* would strengthen the IHC-based screening results, as

Figure 3

Nanostring results for *ALK* rearrangement in 32 paraffinized samples of papillary carcinoma are documented as 3':5' ratio. The background threshold is indicated by a horizontal line. P1–4 indicates patients 1–4 who have *ALK* rearrangements. Other dots indicate patients with native *ALK*. A full colour version of this figure is available via <http://dx.doi.org/10.1530/ERC-14-0467>.

the intensity of staining for phosphorylated *ALK* was correlated with the efficacy of subsequent crizotinib treatments in patients with NSCLC (Yang *et al.* 2014).

The frequencies of *ALK* rearrangement in thyroid cancer have been reported previously (Hamatani *et al.* 2012, Kelly *et al.* 2014, Perot *et al.* 2014). Most recently, researchers from the University of Pittsburgh screened a tissue archive using RT-PCR and identified rearrangements of *ALK* in four of 256 papillary carcinomas (1.6%). These rearrangements included three *STRN*–*ALK* and one *EML4*–rearrangements of *ALK* (Kelly *et al.* 2014). None of the patients carrying rearrangements of *ALK* harbored mutant *BRAF*^{V600E} or had a history of radiation exposure. These investigators also reported an *STRN*–*ALK* rearrangement in a patient with anaplastic carcinoma adjacent to the follicular variant of papillary carcinoma. Although it remains to be determined whether *ALK* is expressed in anaplastic carcinoma, a recent case report has described a remarkable response to crizotinib by a patient with anaplastic carcinoma and multiple lung metastases (Godbert *et al.* 2014).

The clinical profiles of patients with papillary carcinoma with *ALK* rearrangement in this study were similar to those of patients with conventional *BRAF*^{V600E}-driven papillary carcinoma (Xing 2007, Kim *et al.* 2012) with the exception of one young patient who had a relatively large tumor with a solid variant. That patient preferred not to undergo adjuvant radioactive iodine therapy to avoid treatment-related morbidity in the future and maintained a disease-free status, precluding the necessity for further therapy at the time of submission of this manuscript for publication.

A relationship between radiation exposure and *EML4*–*ALK* rearrangement has been suggested in a previous report (Hamatani *et al.* 2012); however, subsequent studies, including ours, failed to identify an association between radiation exposure and rearrangement of *ALK* (Leeman-Neill *et al.* 2013, Kelly *et al.* 2014). The mutual exclusiveness of rearrangement of *ALK* and the *BRAF*^{V600E} mutation as well as with rearrangement of *RET* in this study is consistent with previous reports (Kelly *et al.* 2014, Perot *et al.* 2014) and supports the concept that rearrangement of *ALK* is an independent driver in papillary carcinoma.

Given the high potential of receptor tyrosine kinases as therapeutic targets, systemic approaches are necessary in the future to identify activated kinase fusions. In our study, we explored Nanostring nCounter analysis as a systemic approach that can be multiplexed with as many as 800 different probes. In the Nanostring analysis, the specificity for *ALK* fusion was 100%, indicating its utility as a multikinase screening platform for thyroid cancer. Targeted next-generation sequencing (NGS) may also serve as an alternative multiscreening method (MacConaill 2013, Nikiforov *et al.* 2014). In recent years, NGS techniques capable of sequencing all known oncogenic drivers, including gene rearrangements, have been actively incorporated into clinical practice, and numerous clinical trials have been performed with the molecular targets identified. In thyroid cancer, *BRAF*^{V600E} mutation and *RET* kinase fusions are known to be frequent genomic alterations (Nikiforov & Nikiforova 2011), indicating that these kinases can serve as therapeutic targets in the face of failure of conventional treatment (Brose *et al.* 2014, www.clinicaltrials.gov; identifier number: NCT01876784).

The routine screening for rearrangement of *ALK* for postoperative risk stratification in DTC may not offer a clinical benefit considering the low frequency of rearrangements of *ALK* and the lack of a clear association between rearrangement of *ALK* and poor clinical outcome of thyroid cancer. As there is no indication for targeted therapy in patients that showed good response to conventional treatment, the usefulness of screening of *ALK* with respect to the clinical outcome of DTC should be sought in situations involving patients with advanced disease that is not manageable by surgery or administration of radioactive iodine. Interestingly, a recent prospective screening study has revealed that patients with rearrangements of *ALK* in advanced NSCLC had improved overall survival with an effective targeted therapy than patient without rearrangement of *ALK* after failure of at least one line of chemotherapy (Fallet *et al.* 2014).

A considerable body of evidence now supports the molecular phenotype-stratified approach to cancer care (Willyard 2013). In patients with radioactive-iodine-refractory thyroid cancer, the use of practical diagnostic methodology such as IHC to identify patients with rearrangements of *ALK* is important not only for its immediate influence on care of individual patients but also for the recruitment of a responsive subgroup into a 'basket' trial.

Supplementary data

This is linked to the online version of the paper at <http://dx.doi.org/10.1530/ERC-14-0467>.

Declaration of interest

The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.

Funding

This research was supported by the Seoul National University Hospital (SNUH) & the Seoul National University (SNU) College of Medicine Research Fund (grant number 800-20120032) awarded to W-Y Park.

References

- Brose MS, Nutting CM, Jarzab B, Elisei R, Siena S, Bastholt L, de la Fouchardiere C, Pacini F, Paschke R, Shong YK *et al.* 2014 Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. *Lancet* **384** 319–328. (doi:10.1016/S0140-6736(14)60421-9)
- Chen AY, Jemal A & Ward EM 2009 Increasing incidence of differentiated thyroid cancer in the United States, 1988–2005. *Cancer* **115** 3801–3807. (doi:10.1002/cncr.24416)
- Demeure MJ, Aziz M, Rosenberg R, Gurley SD, Bussey KJ & Carpten JD 2014 Whole-genome sequencing of an aggressive BRAF wild-type papillary thyroid cancer identified EML4–ALK translocation as a therapeutic target. *World Journal of Surgery* **38** 1296–1305. (doi:10.1007/s00268-014-2485-3)
- Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A (Eds) 2010 Thyroid. In *AJCC Cancer Staging Manual*, 7th edn, Ch 8, pp 87–96. New York, NY, USA: Springer.
- Fallet V, Cadranel J, Doubre H, Toper C, Monnet I, Chinnet T, Oliviero G, Foulon G, De Cremoux H, Vieira T *et al.* 2014 Prospective screening for ALK: clinical features and outcome according to ALK status. *European Journal of Cancer* **50** 1239–1246. (doi:10.1016/j.ejca.2014.02.001)
- Fang DD, Zhang B, Gu Q, Lira M, Xu Q, Sun H, Qian M, Sheng W, Ozeck M, Wang Z *et al.* 2014 HIP1–ALK, a novel fusion variant that responds to crizotinib. *Journal of Thoracic Oncology* **9** 285–294. (doi:10.1097/JTO.0000000000000087)
- Garcia-Gonzalez M, Abdulkader I, Boquete AV, Neo XM, Forteza J & Cameselle-Teijeiro J 2005 Cyclooxygenase-2 in normal, hyperplastic and neoplastic follicular cells of the human thyroid gland. *Virchows Archiv* **447** 12–17. (doi:10.1007/s00428-005-1235-1)
- Godbert Y, Henriques de Figueiredo B, Bonichon F, Chibon F, Hostein I, Perot G, Dupin C, Daubech A, Belleanne G, Gros A *et al.* 2014 Remarkable response to crizotinib in woman with anaplastic lymphoma kinase-rearranged anaplastic thyroid carcinoma. *Journal of Clinical Oncology* [in press]. (doi:10.1200/JCO.2013.49.6596)
- Hallberg B & Palmer RH 2013 Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. *Nature Reviews. Cancer* **13** 685–700. (doi:10.1038/nrc3580)
- Hamatani K, Mukai M, Takahashi K, Hayashi Y, Nakachi K & Kusunoki Y 2012 Rearranged anaplastic lymphoma kinase (*ALK*) gene in adult-onset papillary thyroid cancer amongst atomic bomb survivors. *Thyroid* **22** 1153–1159. (doi:10.1089/thy.2011.0511)
- Kelly LM, Barila G, Liu P, Evdokimova VN, Trivedi S, Panebianco F, Gandhi M, Carty SE, Hodak SP, Luo J *et al.* 2014 Identification of the transforming *STRN*–*ALK* fusion as a potential therapeutic target in the aggressive forms of thyroid cancer. *PNAS* **111** 4233–4238. (doi:10.1073/pnas.1321937111)
- Kim TH, Park YJ, Lim JA, Ahn HY, Lee EK, Lee YJ, Kim KW, Hahn SK, Youn YK, Kim KH *et al.* 2012 The association of the *BRAF*^{V600E} mutation with prognostic factors and poor clinical outcome in papillary thyroid cancer: a meta-analysis. *Cancer* **118** 1764–1773. (doi:10.1002/cncr.26500)
- Kim H, Jang SJ, Chung DH, Yoo SB, Sun P, Jin Y, Nam KH, Paik JH & Chung JH 2013 A comprehensive comparative analysis of the histomorphological features of *ALK*-rearranged lung adenocarcinoma based on driver oncogene mutations: frequent expression of epithelial–mesenchymal transition markers than other genotype. *PLoS ONE* **8** e76999. (doi:10.1371/journal.pone.0076999)
- Korea Central Cancer Registry; National Cancer Center 2011 National Cancer Statistics in Korea. <http://ncc.re.kr/english/infor/kccr.jsp>, accessed 26th April 2014.
- Leeman-Neill RJ, Brenner AV, Little MP, Bogdanova TI, Hatch M, Zurnadzy LY, Mabuchi K, Tronko MD & Nikiforov YE 2013 *RET/PTC* and *PAX8/PPARγ* chromosomal rearrangements in post-choybyl thyroid cancer and their association with iodine-131 radiation dose and other characteristics. *Cancer* **119** 1792–1799. (doi:10.1002/cncr.27893)
- Lira ME, Kim TM, Huang D, Deng S, Koh Y, Jang B, Go H, Lee SH, Chung DH, Kim WH *et al.* 2013 Multiplexed gene expression and fusion transcript analysis to detect ALK fusions in lung cancer. *Journal of Molecular Diagnostics* **15** 51–61. (doi:10.1016/j.jmoldx.2012.08.006)
- MacConaill LE 2013 Existing and emerging technologies for tumor genomic profiling. *Journal of Clinical Oncology* **31** 1815–1824. (doi:10.1200/JCO.2012.46.5948)
- Mano H 2012 ALKoma: a cancer subtype with a shared target. *Cancer Discovery* **2** 495–502. (doi:10.1158/2159-8290.CD-12-0009)
- Mazzaferri EL & Kloos RT 2001 Clinical review 128: Current approaches to primary therapy for papillary and follicular thyroid cancer. *Journal of Clinical Endocrinology and Metabolism* **86** 1447–1463. (doi:10.1210/jcem.86.4.7407)
- Mino-Kenudson M, Chirieac LR, Law K, Hornick JL, Lindeman N, Mark EJ, Cohen DW, Johnson BE, Janne PA, Iafrate AJ *et al.* 2010 A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. *Clinical Cancer Research* **16** 1561–1571. (doi:10.1158/1078-0432.CCR-09-2845)
- Nikiforov YE & Nikiforova MN 2011 Molecular genetics and diagnosis of thyroid cancer. *Nature Reviews. Endocrinology* **7** 569–580. (doi:10.1038/nrendo.2011.142)
- Nikiforov YE, Erickson LA, Nikiforova MN, Caudill CM & Lloyd RV 2001 Solid variant of papillary thyroid carcinoma: incidence, clinical–pathologic characteristics, molecular analysis, and biologic behavior. *American Journal of Surgical Pathology* **25** 1478–1484. (doi:10.1097/0000478-200112000-00002)

- Nikiforov YE, Carty SE, Chiosea SI, Coyne C, Duvvuri U, Ferris RL, Gooding WE, Hodak SP, LeBeau SO, Ohori NP *et al.* 2014 Highly accurate diagnosis of cancer in thyroid nodules with follicular neoplasm/suspicious for a follicular neoplasm cytology by ThyroSeq v2 next-generation sequencing assay. *Cancer* **120** 3627–3634. (doi:10.1002/cncr.29038)
- Park HS, Lee JK, Kim DW, Kulig K, Kim TM, Lee SH, Jeon YK, Chung DH & Heo DS 2012 Immunohistochemical screening for anaplastic lymphoma kinase (ALK) rearrangement in advanced non-small cell lung cancer patients. *Lung Cancer* **77** 288–292. (doi:10.1016/j.lungcan.2012.03.004)
- Perot G, Soubeyran I, Ribeiro A, Bonhomme B, Savagner F, Boutet-Bouzamondo N, Hostein I, Bonichon F, Godbert Y & Chibon F 2014 Identification of a recurrent *STRN/ALK* fusion in thyroid carcinomas. *PLoS ONE* **9** e87170. (doi:10.1371/journal.pone.0087170)
- Schlumberger MJ 1998 Papillary and follicular thyroid carcinoma. *New England Journal of Medicine* **338** 297–306. (doi:10.1056/NEJM199801293380506)
- Shaw AT, Hsu PP, Awad MM & Engelman JA 2013 Tyrosine kinase gene rearrangements in epithelial malignancies. *Nature Reviews. Cancer* **13** 772–787. (doi:10.1038/nrc3612)
- Siegel R, Ma J, Zou Z & Jemal A 2014 Cancer statistics, 2014. *CA: A Cancer Journal for Clinicians* **64** 9–29. (doi:10.3322/caac.21208)
- Suehara Y, Arcila M, Wang L, Hasanovic A, Ang D, Ito T, Kimura Y, Drilon A, Guha U, Rusch V *et al.* 2012 Identification of *KIF5B-RET* and *GOPC-ROS1* fusions in lung adenocarcinomas through a comprehensive mRNA-based screen for tyrosine kinase fusions. *Clinical Cancer Research* **18** 6599–6608. (doi:10.1158/1078-0432.CCR-12-0838)
- Swerdlow S, Campo E, Harris N, Jaffe ES, Pileri SA, Stein H, Thiele J & Vardiman JW (Eds) 2008 In *WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues*, 4th edn, Ch 11, pp 269–320. Lyon, France: IARC Press.
- Vaisman F, Tala H, Grewal R & Tuttle RM 2011 In differentiated thyroid cancer, an incomplete structural response to therapy is associated with significantly worse clinical outcomes than only an incomplete thyroglobulin response. *Thyroid* **21** 1317–1322. (doi:10.1089/thy.2011.0232)
- Willyard C 2013 'Basket studies' will hold intricate data for cancer drug approvals. *Nature Medicine* **19** 655. (doi:10.1038/nm0613-655)
- Xing M 2007 *BRAF* mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implications. *Endocrine Reviews* **28** 742–762. (doi:10.1210/er.2007-0007)
- Yang JJ, Zhang XC, Su J, Xu CR, Zhou Q, Tian HX, Xie Z, Chen HJ, Huang YS, Jiang BY *et al.* 2014 Lung cancers with concomitant *EGFR* mutations and *ALK* rearrangements: diverse responses to EGFR-TKI and crizotinib in relation to diverse receptors phosphorylation. *Clinical Cancer Research* **20** 1383–1392. (doi:10.1158/1078-0432.CCR-13-0699)
- Yi ES, Boland JM, Maleszewski JJ, Roden AC, Oliveira AM, Aubry MC, Erickson-Johnson MR, Caron BL, Li Y, Tang H *et al.* 2011 Correlation of IHC and FISH for *ALK* gene rearrangement in non-small cell lung carcinoma: IHC score algorithm for FISH. *Journal of Thoracic Oncology* **6** 459–465. (doi:10.1097/JTO.0b013e318209edb9)

Received in final form 5 November 2014

Accepted 19 November 2014